ArticleMolecular and clinical oncology2017

Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis.

Javier Garde Noguera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.